Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ805MR)

This product GTTS-WQ805MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ805MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15454MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ9611MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ12831MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
GTTS-WQ6297MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ7091MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ3064MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ14431MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ8285MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW